INT69314

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1997
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 16
Total Number 16
Disease Relevance 1.78
Pain Relevance 2.19

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
plasma 1
liver 1
CYP3A (Homo sapiens)
CYP3A - P4503A (1)
Pain Link Frequency Relevance Heat
rapifen 17 100.00 Very High Very High Very High
Oxycodone 12 99.84 Very High Very High Very High
dexamethasone 125 99.82 Very High Very High Very High
antagonist 42 99.64 Very High Very High Very High
Opioid 3 97.34 Very High Very High Very High
Bioavailability 10 96.40 Very High Very High Very High
Versed 4 93.76 High High
analgesia 2 92.44 High High
Antihistamine 4 91.92 High High
qutenza 1 71.36 Quite High
Disease Link Frequency Relevance Heat
Miosis 1 100.00 Very High Very High Very High
Vomiting 166 99.04 Very High Very High Very High
Toxicity 21 97.12 Very High Very High Very High
Hepatotoxicity 7 91.48 High High
Exanthema 19 91.40 High High
Staphylococcus Infection 2 88.08 High High
Syndrome 3 86.80 High High
Bullous Skin Disease 1 85.76 High High
Acquired Immune Deficiency Syndrome Or Hiv Infection 147 75.00 Quite High
Infection 45 75.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
BACKGROUND: Because inhibition of the first-pass metabolism of terfenadine may be associated with fatal arrhythmia, we assessed the possibility that fluoxetine inhibits this metabolism as a model for CYP3A drug interactions.
CYP3A Binding (interactions) of
1) Confidence 0.48 Published 1997 Journal Clin. Pharmacol. Ther. Section Body Doc Link 9433393 Disease Relevance 0 Pain Relevance 0
It is an inactive prodrug hydrolyzed in vivo to the active inhibitor valdecoxib, a substrate for hepatic cytochrome P450 3A4 (CYP3A4); hence, a potential exists for metabolic interactions with other CYP3A substrates.
CYP3A Binding (interactions) of
2) Confidence 0.48 Published 2003 Journal Anesthesiology Section Abstract Doc Link 12657846 Disease Relevance 0 Pain Relevance 0.35
When treating breakthrough pain, with careful attention to maximal mucosal absorption and minimal swallowing, CYP3A variability and drug interactions are unlikely to affect the onset or magnitude of OTF analgesia; however, duration may be affected.


CYP3A Binding (interactions) of
3) Confidence 0.47 Published 2004 Journal Anesthesiology Section Body Doc Link 15329598 Disease Relevance 0 Pain Relevance 0
BACKGROUND AND OBJECTIVES: Systemic clearance of the opioid alfentanil after intravenous administration is an excellent in vivo probe for hepatic cytochrome P4503A (CYP3A) activity and drug interactions.
CYP3A (P4503A) Binding (interactions) of associated with rapifen, opioid and miosis
4) Confidence 0.44 Published 2003 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 12621385 Disease Relevance 0.10 Pain Relevance 0.45
Quinidine and lignocaine, although they are substrates of CYP3A, showed preferential inhibition over the O-demethylation of codeine, suggesting a low affinity to the CYP3A.
CYP3A Binding (affinity) of
5) Confidence 0.36 Published 1997 Journal Eur. J. Clin. Pharmacol. Section Body Doc Link 9143866 Disease Relevance 0 Pain Relevance 0
Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
CYP3A Binding (contribution) of in liver associated with oxycodone
6) Confidence 0.34 Published 2004 Journal Drug Metab. Dispos. Section Title Doc Link 15039299 Disease Relevance 0 Pain Relevance 0.44
Thus, co-administration of risperidone with CYP3A inducer(s), including rifampin should be recognized or avoided in clinical practice.


CYP3A Binding (recognized) of
7) Confidence 0.34 Published 2007 Journal J Clin Pharm Ther Section Body Doc Link 17381666 Disease Relevance 0 Pain Relevance 0
Interindividual variability and drug interactions affecting intestinal transporter and hepatic CYP3A and CYP2B6 activity may alter methadone disposition.


CYP3A Binding (interactions) of
8) Confidence 0.33 Published 2004 Journal Clin. Pharmacol. Ther. Section Body Doc Link 15371986 Disease Relevance 0 Pain Relevance 0
Dexamethasone is also metabolized by CYP3A and is a weak inducer of CYP3A after prolonged exposure or repeat-dose administration [7, 18].
CYP3A Binding (metabolized) of associated with dexamethasone
9) Confidence 0.28 Published 2009 Journal Support Care Cancer Section Body Doc Link PMC2726912 Disease Relevance 0.34 Pain Relevance 0.51
CONCLUSIONS AND IMPLICATIONS: Drug-drug interactions via CYP2D6 and CYP3A affected oxycodone pharmacokinetics and its magnitude depended on CYP2D6 genotype.


CYP3A Binding (interactions) of
10) Confidence 0.22 Published 2010 Journal Br. J. Pharmacol. Section Body Doc Link 20590587 Disease Relevance 0 Pain Relevance 0
It is believed that this naringin mainly inhibits the enzyme (CYP3A) that metabolizes calcium antagonists.
CYP3A Binding (metabolizes) of associated with antagonist
11) Confidence 0.20 Published 2008 Journal Nutr Metab (Lond) Section Body Doc Link PMC2584094 Disease Relevance 0 Pain Relevance 0.24
Phenotyping for CYP2D6 (with dextromethorphan) and CYP3A (with midazolam) were assessed at each session.
CYP3A Binding (Phenotyping) of
12) Confidence 0.17 Published 2010 Journal Br. J. Pharmacol. Section Body Doc Link 20590587 Disease Relevance 0 Pain Relevance 0
Initiation of half-dose nevirapine therapy, followed by stepwise dose escalation over a two-week period allows for autoinduction of cytochrome p450 metabolizing enzymes CYP3A and 2B6, resulting in increased drug clearance and decreased cutaneous toxicity.
CYP3A Binding (autoinduction) of associated with toxicity
13) Confidence 0.17 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2701488 Disease Relevance 0.88 Pain Relevance 0.03
Darunavir is primarily metabolized by the hepatic cytochrome P450 (CYP) enzymes, primarily CYP3A.
CYP3A Binding (metabolized) of
14) Confidence 0.16 Published 2009 Journal Drugs Section Abstract Doc Link 19323590 Disease Relevance 0.29 Pain Relevance 0.09
Extensive pulegone metabolism generated p-cresol that was a glutathione depletory, whereas the furan ring of the diterpenoids in germander was oxidized by CYP3A4 to reactive epoxide which can inactivate hepatic CYP3A and epoxide hydrolase through covalent binding.
CYP3A Binding (binding) of
15) Confidence 0.07 Published 2007 Journal Curr. Drug Metab. Section Abstract Doc Link 17691916 Disease Relevance 0.17 Pain Relevance 0.07
These studies enrolled a limited number of patients, but it seems likely that casopitant can be administered safely with drugs metabolized by CYP3A4, such as cyclophosphamide and docetaxel.36,37 Vinorelbine and etoposide, (likely to be co-administered with cisplatin), are metabolized by CYP3A, potentially leading to increased plasma levels of these agents when co-administered with casopitant.
CYP3A Binding (metabolized) of in plasma
16) Confidence 0.06 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697542 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox